KalVista Pharmaceuticals Reports Phase 3 Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema February 23, 2024
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases January 4, 2024
Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease December 19, 2023
